Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Phar-Mor submits two new reorganization plans; Haft Group offers to buy 30.8% stake.

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

PHAR-MOR ALTERNATE REORGANIZATION PLANS WOULD GRANT UNSECURED CREDITORS 13.8% of the company's new common stock and warrants to purchase 9.3% of the fully diluted common shares for $7 per share, Phar-Mor announced April 24. Unsecured creditors also will be paid from any proceeds the deep-discount chain receives from lawsuits it has filed, including a lawsuit against previous auditor Cooper & Lybrand, Phar-Mor said. In addition, creditors with reclamation claims will receive approximately $24.5 mil. in cash under the plan.

Table

View full table

Tags:
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

RS001586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By